Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3, double-blind ...
Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated at all doses (0.1 to 20 mg/kg) in six cohorts. Total AP inhibition was achieved through all cohorts and the ...
SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback